Allergan Aesthetics has secured FDA approval for Skinvive by Juvéderm for improvement of neck appearance, marking the first Juvéderm indication specifically cleared for the neck and décolletage. The product is a smooth, cohesive gel formulation designed to address loss of elasticity and fine lines in this notoriously difficult-to-treat zone.
Injectables
Allergan Aesthetics Wins FDA Approval for Skinvive by Juvéderm — Neck Indication Expands Filler Portfolio
AbbVie's newest Juvéderm indication targets neck laxity and wrinkles, adding a high-margin treatment to the injectable mix.
Neck treatment commands premium pricing—often 1.5× to 2× the per-syringe margin of cheek or lip work.
For practice owners, this is a direct revenue play. Neck treatment commands premium pricing—often 1.5× to 2× the per-syringe margin of cheek or lip work—because it requires precision, volume, and repeat sessions. Skinvive's approval gives you a branded, FDA-cleared entry point into a market previously dominated by off-label Juvéderm Ultra XC or Volbella. The indication also sits squarely in the Allē loyalty ecosystem, meaning rebate velocity and per-unit economics will track with AbbVie's broader toxin and filler bundling strategy.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.